Denali Therapeutics (DNLI) Price & Analysis

Compare

737 Followers

DNLI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.57 - $33.33

Previous CloseN/A

Volume399.31K

Average Volume (3M)1.71M

Market Cap

$2.27B

Enterprise Value$1.55B

Total Cash (Recent Filing)$898.95M

Total Debt (Recent Filing)$46.56M

Price to Earnings (P/E)―

Beta2.21

Next Earnings

Oct 30, 2025

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding146,212,280

10 Day Avg. Volume1,697,204

30 Day Avg. Volume1,710,606

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.68

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-507.78

Enterprise Value/Ebitda-3.02

Forecast

1Y Price Target

$33.29

Price Target Upside113.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company ended the quarter with ~$977M in cash which it expects to fund operations into 2028.

Regulatory ApprovalDenali's BLA for tividenofusp alfa has been accepted by the FDA for accelerated approval, with a priority review and no advisory committee meeting expected.

Technological AdvancementThe priority review for DNL310 and surrogate endpoint alignment for DNL 126 reinforce the belief that Denali’s Transport Vehicle (TV) technology can unlock CNS delivery and fast track regulatory pathways in rare diseases.

Bears Say

Clinical TrialsThe ongoing Phase 2/3 COMPASS study will support global regulatory submission for tividenofusp alfa.

Market CompetitionDenali is well-positioned to navigate the challenges which Elaprase faced with a more sophisticated launch strategy for tividenofusp alfa.

Unmet Medical NeedsThere are currently no approved treatments for Sanfilippo syndrome Type A, indicating an unmet medical need that Denali's treatment could address.

Denali Therapeutics News

Denali Therapeutics reports Q2 EPS (72c), consensus (74c)

Cash, cash equivalents, and marketable securities were approximately $977.4M as of June 30. “The FDA’s priority review of...

17d ago

DNLI

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Leerink Partners analyst Marc Goodman has maintained their bullish stance on DNLI stock, giving a Buy rating yesterday....

14d ago

DNLI

Denali Therapeutics: Advancements in CNS Delivery and Strategic Market Positioning Drive Buy Rating

Denali Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from...

17d ago

DNLI

Denali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating yesterday....

17d ago

DNLI

Denali Therapeutics Advances in Neurodegenerative Treatments

Denali Therapeutics ( ($DNLI) ) has released its Q2 earnings. Here is a breakdown of the information Denali...

17d ago

DNLI

Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy Rating

TD Cowen analyst Joseph Thome has maintained their bullish stance on DNLI stock, giving a Buy rating on...

17d ago

DNLI

Royalty Pharma appoints Ho, Weatherman to board of directors

Royalty Pharma (RPRX) announced the appointment of Carole Ho and Elizabeth Weatherman to its Board of Directors, effective...

1M ago

DNLI

RPRX

Denali Therapeutics: Promising Developments and Strategic Focus Drive Buy Rating

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, with a...

2M ago

DNLI

Denali Therapeutics’ Promising Developments and FDA Milestones Support Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating on...

2M ago

DNLI

Denali noted no FDA panel meeting in call with William Blair

William Blair keeps an Outperform rating on Denali Therapeutics (DNLI) after the company announced that a biologics license...

2M ago

DNLI

Denali Therapeutics’ FDA Priority Review for New Therapy

Denali Therapeutics ( ($DNLI) ) has shared an announcement. On July 7, 2025, Denali Therapeutics announced that the...

2M ago

DNLI

Denali announces FDA acceptance, priority review for tividenofusp alfa BLA

Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration has accepted for review the Biologics License...

2M ago

DNLI

Denali Therapeutics Enters Registration Rights Agreement

Denali Therapeutics ( ($DNLI) ) has provided an update. On June 3, 2025, Denali Therapeutics entered into a...

3M ago

DNLI

Denali Therapeutics price target lowered to $27 from $28 at BofA

BofA analyst Tazeen Ahmad lowered the firm’s price target on Denali Therapeutics (DNLI) to $27 from $28 and...

3M ago

DNLI

DNLI FAQ

What was Denali Therapeutics’s price range in the past 12 months?

Denali Therapeutics lowest stock price was $10.57 and its highest was $33.33 in the past 12 months.

What is Denali Therapeutics’s market cap?

Denali Therapeutics’s market cap is $2.27B.

When is Denali Therapeutics’s upcoming earnings report date?

Denali Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.

How were Denali Therapeutics’s earnings last quarter?

Denali Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.01.

Is Denali Therapeutics overvalued?

According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Denali Therapeutics pay dividends?

Denali Therapeutics does not currently pay dividends.

What is Denali Therapeutics’s EPS estimate?

Denali Therapeutics’s EPS estimate is -0.75.

How many shares outstanding does Denali Therapeutics have?

Denali Therapeutics has 146,212,280 shares outstanding.

What happened to Denali Therapeutics’s price movement after its last earnings report?

Denali Therapeutics reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went down -5.029%.

Which hedge fund is a major shareholder of Denali Therapeutics?

Currently, no hedge funds are holding shares in DNLI

Denali Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-39.69%

Trailing 12-Months

Asset Growth

-22.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics (DNLI) Earnings & Revenues

Historic Earnings Reports

DNLI Stock 12 Month Forecast

Average Price Target

$33.29

▲(113.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","26":"$26","41":"$41","18.5":"$18.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,18.5,26,33.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,15.483076923076922,17.526153846153846,19.56923076923077,21.612307692307695,23.65538461538462,25.69846153846154,27.74153846153846,29.784615384615385,31.82769230769231,33.870769230769234,35.91384615384616,37.95692307692308,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,14.966923076923077,16.493846153846153,18.020769230769233,19.54769230769231,21.074615384615385,22.60153846153846,24.128461538461536,25.655384615384616,27.182307692307695,28.70923076923077,30.236153846153847,31.763076923076923,{"y":33.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,14.483076923076922,15.526153846153846,16.569230769230767,17.61230769230769,18.655384615384612,19.698461538461537,20.74153846153846,21.784615384615385,22.827692307692306,23.870769230769227,24.91384615384615,25.956923076923076,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >